Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21479617 | 0.81 | SLC6A4 (0.46) | SLC6A4 | |
| SCHEMBL6533341 | 0.75 | — | — | |
| SCHEMBL25165279 | 0.73 | — | — | |
| SCHEMBL28010763 | 0.73 | — | — | |
| SCHEMBL4584287 | 0.73 | — | — | |
| SCHEMBL175677 | 0.71 | — | — | |
| SCHEMBL27345975 | 0.71 | — | — | |
| Hydrochloric Acid SCHEMBL10605683 | 0.71 | — | — | |
| SCHEMBL2330007 | 0.70 | — | — | |
| SCHEMBL4314997 | 0.70 | SLC6A4 (0.41) | SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7459455-B2 | Pyrimidine compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-02 | — | — | US | disclosed |
| US-20050085637-A1 | Antiproliferative agents; angiogenesis inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-04-21 | — | — | US | disclosed |
| EP-1472233-A1 | PYRIMIDINE COMPOUNDS | SmithKline Beecham Corporation (US) | 2004-11-03 | — | — | EP | disclosed |
| WO-2003066601-A1 | PYRIMIDINE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085637-A1 | Antiproliferative agents; angiogenesis inhibitors | TIE1, TEK, KDR | SLC6A4 4136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.